During the past decades, with the introduction of the recombinant DNA, hybridoma and transgenic technologies there has been an exponential evolution in understanding the pathogenesis, diagnosis and treatment of a large number of human diseases. The technologies are evident with the development of cytokines and monoclonal antibodies as therapeutic agents and the techniques used in gene therapy. Immunopharmacology is that area of biomedical sciences where immunology, pharmacology and pathology overlap. It concerns the pharmacological approach to the immune response in physiological as well as pathological events. This goals and objectives of this textbook are to emphasize the developments in immunology and pharmacology as they relate to the modulation of immune response. The information includes the pharmacology of cytokines, monoclonal antibodies, mechanism of action of immune-suppressive agents and their relevance in tissue transplantation, therapeutic strategies for the treatment of AIDS and the techniques employed in gene therapy. The book is intended for health care professional students and graduate students in pharmacology and immunology.

Paralleling the discovery of HIV and the rise of the AIDS pandemic, a flock of naysayers has dedicated itself to replacing genuine knowledge with destructive misinformation—and spreading from the fringe to the mainstream media and the think tank. Now from the editor of the journal AIDS and Behavior comes a bold exposé of the scientific and sociopolitical forces involved in this toxic evasion. Denying AIDS traces the origins of AIDS dissidents disclaimers during the earliest days of the epidemic and delves into the psychology and politics of the current denial movement in its various incarnations. Seth Kalichman focuses not on the “difficult” or doubting patient, but on organized, widespread forms of denial (including the idea that HIV itself is a myth and HIV treatments are poison) and the junk science, faulty logic, conspiracy theories, and larger forces of homophobia and racism that fuel them. The malignant results of AIDS denial can be seen in those individuals who refuse to be tested, ignore their diagnoses, or reject the treatments that could save their lives. Instead of ignoring these currents, asserts Kalichman, science has a duty to counter them. Among the topics covered: Why AIDS denialism endures, and why science must understand it. Pioneer virus HIV researcher Peter Duesberg’s role in AIDS denialism. Flawed immunological, virological, and pharmacological pseudoscience studies that are central to texts of denialism. The social conservative agenda and the politics of AIDS denial, from the courts to the White House. The impact of HIV misinformation on public health in South Africa. Fighting fiction with reality: anti-denialism and the scientific community. For anyone affected by, interested in, or working with researchers in HIV/AIDS, and public health professionals in general, the insight and vision of Denying AIDS will inspire outrage, discussion, and ultimately action. See http://denyingaids.blogspot.com/ for more information.

During the last 5 years, major advances have been made in our understanding of the pathogenesis of human immunodeficiency virus (HIV) disease and in the development of new potent antiviral agents. With regard to HIV pathogenesis, several recent observations have not only changed our perspectives of HIV disease, but have been critical for the design of therapeutic strategies.

The field of pharmaceutical biotechnology is evolving rapidly. A whole new arsenal of protein pharmaceuticals is being produced by recombinant techniques for cancer, viral infections, cardiovascular and hereditary disorders, and other diseases. In addition, scientists are confronted with new technologies such as polymerase chain reactions, combinatorial chemistry and gene therapy. This introductory textbook provides extensive coverage of both the basic science and the applications of biotechnology-produced pharmaceuticals, with special emphasis on their clinical use. Pharmaceutical Biotechnology serves as a complete one-stop source for undergraduate pharmacists, and it is valuable for researchers and professionals in the pharmaceutical industry as well.

This volume summarizes recent advances in understanding the mechanisms of HIV-1 latency, in characterizing residual viral reservoirs, and in developing targeted interventions to reduce HIV-1 persistence during antiretroviral therapy. Specific chapters address the molecular mechanisms that govern and regulate HIV-1 transcription and latency; assays and technical approaches to quantify viral reservoirs in humans and animal models; the complex interchange between viral reservoirs and the host immune system; computational strategies to model viral reservoir dynamics; and the development of therapeutic approaches that target viral reservoir cells. With contributions from an interdisciplinary group of investigators that cover a broad spectrum of subjects, from molecular virology to proof-of-principle clinical trials, this book is a valuable resource for basic scientists, translational investigators, infectious-disease physicians, individuals living with HIV/AIDS and the general public.

Autoimmune diseases are diverse and responsible for considerable morbidity. Their etiology remains largely unknown, and current therapy with anti-inflammatory drugs is prone to adverse effects, and rarely curative. New therapies with anti-cytokine antibodies or receptors are promising, but require frequent administration of expensive protein drugs. Gene Therapy of Autoimmune Diseases comprehensively reviews research in gene therapy for autoimmune diseases with viral or non-viral vectors. Gene therapy offers the possibility of long-term, continuous delivery of a wide variety of immunosuppressive, anti-inflammatory, or tolerance-inducing agents. Moreover, highly specific genetically modified cells can be produced. This book discusses the most promising avenues in this exciting new field.

Tremendous progress in the understanding of the immune pathogenesis of HIV disease has been made in the last two decades like in no other field of science ever before. Besides the inhibition of viral replication with highly active antiretroviral therapy (HAART) immunoreconstitution remains an important mainstay to be achieved in the battle against HIV. Intensive research has led to worldwide phase-III studies of immunotreatment of HIV infection such as the SILCAAT and ESPRIT trials to boost existing immune responses and to restore the immune system leading to the control of viral replication. The science and practical management of immunotherapy of HIV patients is described by famous experts from immunology, virology, gene therapy, dermatology, and clinical medicine.